Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Chougule, Anuradha ^a   Prabhash, Kumar ^a   Noronha, Vanita ^a   Joshi, Amit ^a   Thavamani, Abhishek ^a   Chandrani, Pratik ^a   Upadhyay, Pawan ^a   Utture, Sagarika ^a   Desai, Saral ^a   Jambhekar, Nirmala ^a   Dutt, Amit ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; EAST ASIAN; ETHNIC DIFFERENCE; ETHNICITY; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; INCIDENCE; INDIAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SMOKING; SOUTHEAST ASIA; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84885029292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076164     Document Type: Article

References (37)

1. Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, et al. (2012) Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer 49: 74-81.
2. Ferlay JSH, Bray F, Forman D, Mathers C and Parkin DM (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer Available: http://globocan.iarc.fr. Accessed 2013 Jul 2.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246.
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
9. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
10. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, et al. (2012) Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18: 6169-6177.
11. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, et al. (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081-1086.
12. Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, et al. (2011) Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 6: 28-31.
13. Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, et al. (2007) Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2: 430-439.
14. Kim HJ, Oh SY, Kim WS, Kim SJ, Yoo GH, et al. (2013) Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncol Lett 5: 271-276.
15. Pan-Chyr Yang YS, Joseph Siu-KieAu,et al (2012) Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma. J Clin Oncol 30.
16. Noronha V, Prabhash K, Thavamani A, Chougule A, Purandare N, et al. (2013) EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. PLoS One 8: e61561.
17. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, et al. (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73: 316-319.
18. ShyamAggarwal S, SachinMinhans, Manish Pungliya, Soumitra N (2012) A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients. J Clin Oncol 30, 2012 (abstr e18041).
19. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, et al. (2004) Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164: 35-42.
20. Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castella E, et al. (2008) A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3: 1224-1235.
21. Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, et al. (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384.
22. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, et al. (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11: 6816-6822.
23. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923.
24. Sun YH, Fang R, Gao B, Han XK, Zhang JH, et al. (2010) Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacol Sin 31: 647-648.
25. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, et al. (2010) Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 126: 651-655.
26. Zhang Y, Sun Y, Pan Y, Li C, Shen L, et al. (2012) Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 18: 1947-1953.
27. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 2879-2882.
28. Li M, Zhang Q, Liu L, Liu Z, Zhou L, et al. (2011) The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma 58: 74-81.
29. Sun MH, Yang F, Shen L, Zhang L, Chen Y, et al. (2011) [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types]. Zhonghua Bing Li Xue Za Zhi 40: 655-659.
30. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, et al. (2013) Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn.
31. Gazdar AF, (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28Suppl 1: S24-31.
32. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203.
33. Kumar A, Petri ET, Halmos B, Boggon TJ, (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-1751.
34. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
35. Suda K, Onozato R, Yatabe Y, Mitsudomi T, (2009) EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4: 1-4.
36. Reich D, Thangaraj K, Patterson N, Price AL, Singh L, (2009) Reconstructing Indian population history. Nature 461: 489-494.
37. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, et al. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41: 450-454.